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A two-step, automated, high-throughput RNAi
silencing screen was used to identify host cell
factors required during vaccinia virus infection.
Validation and analysis of clustered hits revealed
previously unknown processes during virus entry,
including a mechanism for genome uncoating. Viral
core proteins were found to be already ubiquiti-
nated during virus assembly. After entering the
cytosol of an uninfected cell, the viral DNA was
released from the core through the activity of the
cell’s proteasomes. Next, a Cullin3-based ubiquitin
ligase mediated a further round of ubiquitination
and proteasome action. This was needed in order
to initiate viral DNA replication. The results accen-
tuate the value of large-scale RNAi screens in
providing directions for detailed cell biological in-
vestigation of complex pathways. The list of cell
functions required during poxvirus infection will,
moreover, provide a resource for future virus-host
cell interaction studies and for the discovery of
antivirals.INTRODUCTION
Poxviruses are enveloped DNA viruses characterized by their
large size, intricate structure, and a complex cytoplasmic repli-
cation cycle (Moss et al., 2007). Vaccinia virus (VACV), the
prototypic poxvirus used in this study, served as a vaccine
during the eradication of smallpox, one of the most devas-
tating diseases of the 20th century (Moss et al., 2007). The
potential deployment of the smallpox virus as a biological
weapon, risks associated with resumed vaccination, and recent
monkeypox outbreaks warrant continued research toward new
antipoxvirus agents (Di Giulio and Eckburg, 2004; Harrison
et al., 2004).1036 Cell Reports 2, 1036–1047, October 25, 2012 ª2012 The AuthoThe VACV lifecycle begins with macropinocytic internalization
of the virus into host cells (Huang et al., 2008; Mercer and Helen-
ius, 2008). This is followed by low pH-dependent membrane
fusion to release the viral core into the cytosol (Townsley et al.,
2006). Postpenetration steps include loss of core-associated
lateral bodies, core expansion, and transcription of early viral
genes within the expanded core (Dales, 1963; Kates and Bee-
son, 1970; Moss, 1990; Pedersen et al., 2000). Early messenger
RNAs (mRNAs) generate about 100 different viral proteins,
including unidentified factors required for DNA uncoating (Joklik,
1964b; Magee and Miller, 1968). During the subsequent
uncoating process, cores disappear as visible structures, the
viral DNA is released and replicated, intermediate and late genes
are expressed, and cytosolic virus factories are formed. While
many of the cellular factors and functions required for initial entry
have been described (Huang et al., 2008; Laliberte et al., 2011;
Mercer and Helenius, 2008; Schmidt et al., 2012; Townsley
et al., 2006), the cellular factors that participate in viral genome
uncoating remain largely undefined.
In the last few years, large-scale RNAi screening has become
a powerful tool for the analysis of pathogen-host interactions.
This approach has been previously applied to a variety of
pathogens (reviewed in Cherry, 2009). For VACV, a Drosophila
kinome screen was used to identify and describe a role for
AMP-activated protein kinase (AMPK) during infection (Moser
et al., 2010).
Our goal was to elucidate the host factors in human tissue
culture cells needed in the VACV life cycle. Using a large-
scale RNAi screen, we identified critical cellular processes that
the virus exploits during infection. By focusing our validation
studies on protein clusters involved in ubiquitin-mediated
proteasome degradation, which has been previously implicated
in poxvirus DNA replication (Satheshkumar et al., 2009;
Teale et al., 2009), we uncovered additional roles for protea-
somes and ubiquitination in virus assembly and genome
uncoating. In addition, we identified a Cullin3-based ubiquitin
ligase, as required for VACV genome replication. Ultimately,
this information could facilitate the development of novel
antiviral agents that would target the host rather than the virus
directly.rs
RESULTS
RNAi Screening Identifies 188 Cellular Factors Required
for VACV Infection
We used an automated, high-content, high-throughput RNAi
screen in human tissue culture cells (HeLa) to identify host
cell factors and processes required during the VACV life
cycle. Using the mature virion (MV) form of a recombinant
VACV that expresses enhanced green fluorescent protein
(EGFP) under a synthetic early/late viral promoter (VACV-
EGFP) (Mercer and Helenius, 2008), we could readily distinguish
infected from noninfected cells based on EGFP expression 8 hr
postinfection (hpi). Automated fluorescence microscopy and
image analysis was employed to score for cell factors required
during the replication cycle, up to and including translation of
late viral genes, without distinguishing between early and late
defects.
To avoid some of the pitfalls encountered in previous virus
infection screens (Cherry, 2009; Mohr et al., 2010), we chose
to screen a set of 7,000 genes selected for their potential to be
inhibited by small compounds (the 7,000 druggable genome
library; QIAGEN). Although covering only one-third of human
genes, these represent a well-studied and well-annotated
cross-section of the full genome, and for these factors, inhibitors
and other reagents are more readily available for follow-up
studies. In addition, we improved image analysis, hit visualiza-
tion, and hit validation (Extended Experimental Procedures;
Figure S1; Bray et al., 2012; Snijder et al., 2012).
To increase reliability, we introduced a fully automated
computational pipeline for high-content image analysis
(Carpenter et al., 2006; Snijder et al., 2009). Over 200 quantitative
features were extracted from each of 624 million individual cells
from 1.45 million images (Carpenter et al., 2006). Using these
features as a basis, several iterations of supervised machine
learning were applied to identify virus infection, mitosis,
apoptosis, and technical phenotypes (Ra¨mo¨ et al., 2009; Snijder
et al., 2009) (see Extended Experimental Procedures for details).
Cell number and density (population-context) effects were
normalized to improve both reproducibility of screening results
in different cell lines and consistency of phenotypes obtained
by different small interfering RNAs (siRNAs) targeting the same
gene (Snijder et al., 2012).
The RNAi screen was carried out in two steps, as detailed in
Figure 1A and in experimental procedures. Three nonoverlap-
ping siRNAs against each gene were used in a primary screen
and three additional siRNAs in a secondary follow-up screen.
Both screens were repeated independently three times. The
primary screen using the 7,000 druggable genomes led to the
identification of 276 genes, in which two or three of the three
siRNAs reduced VACV infection relative to controls (i.e., for the
majority, the median over the triplicates of at least two siRNAs
had a median absolute deviation less than 1.5 over the whole
screen). To provide a resource for future studies of poxvirus–
host cell interaction, the full set of images and analysis results
have been made available (see Web Resources).
The secondary screen directed against the genes identified as
hits in the primary screen was performed using siRNAs from
a different vendor (Ambion). It confirmed 68% of the hits fromCellthe primary screen with a correlation coefficient of 0.34
between the validated RNAi phenotypes of the two screens
(p = 2.8 3 106). A stringent, control-based analysis of nontar-
geting control siRNAs gave a false positive rate of 0.06% in the
secondary screen, giving further confidence in the confirmed
host factors.
The final hit list shown in Table S1 had 188 genes, represent-
ing a broad range of cell functions. Among them, several
proteins have been previously implicated in VACV infection:
EGFR, RAC1, PAK1, laminin (LAMA1 and 2), the proteasome,
Tsg101, profilin, and RIPK3 (Chiu et al., 2007; Cho et al.,
2009; Eppstein et al., 1985; Honeychurch et al., 2007; Li
et al., 2008; Locker et al., 2000; Mercer and Helenius, 2008;
Mercer et al., 2010; Satheshkumar et al., 2009; Teale et al.,
2009; Villa et al., 2010). In the only other high-throughput
RNAi screen directed against VACV, Moser et al. screened
440 unique Drosophila genes and identified seven hits, of
which the human orthologs are PRKAA2, PRKAG2, PRKAB1,
PIKfyve, PIK3C2A, STAM, and PTPN23 (Moser et al., 2010).
Of these, we identified PRKAB1 and PTPN23 (Figure 1B; Table
S1). While no exact match for PIK3C2A was found, PI4KB and
FRAP1 were hits, further highlighting the importance of phos-
phoinositide-kinase activity for VACV infection (McNulty et al.,
2010; Mercer and Helenius, 2008; Moser et al., 2010). Other
hits, such as ribosomal proteins, were expected for any virus.
However, the majority of hits had no prior connection to
VACV infection.
To extract information regarding critical processes in the
infection cycle, the list was submitted to rigorous bioinformatic
analysis. For this, we developed an algorithm that combined
functional- and interaction-based information. This algorithm
has been made available (see Supplemental Network Visualiza-
tion Algorithm) and is applicable for the visualization and analysis
of any gene list. The hits were first assigned to ‘‘functional anno-
tation clusters,’’ representing sets of proteins that share
common annotations within public databases [DAVID; (Huang
da et al., 2009)]. As shown in Table S2 and Figure S2, the genes
were enriched within 13 clusters and several highly connected
functional annotation networks.
The function-based information was combined with data on
protein interactions between individual host factors (STRING;
Szklarczyk et al., 2011). The result of the combined analysis is
shown for 126 of the 188 host factors in Figure 1B. Automatic
annotation was used to visualize the interaction networks (yellow
to red lines) both within and between functional annotation
clusters (gray dashed boxes). Without going into detail, it was
evident that, although replication and assembly of progeny virus
occurs in the cytoplasm of host cells, VACV depends on cyto-
plasmic as well as nuclear factors. Since the nucleus and its
many functions, such as splicing and nuclear pore complex
function, have been largely ignored with regard to the infectious
lifecycle of poxviruses, these findings are likely to open new
avenues in VACV research. The cytoplasmic functions included
membrane trafficking, signaling, proteolysis, and ion transport.
Factors in the tyrosine kinase and actin clusters have already
been shown to be necessary for phosphatidylserine-mediated
macropinocytosis of the virus during entry (Mercer and Helenius,
2008; Mercer et al., 2010).Reports 2, 1036–1047, October 25, 2012 ª2012 The Authors 1037
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VACV Core Breakdown Requires Proteasome Activity,
but Is Independent of New Ubiquitination
In the follow-up, we focused on two prominent clusters: the pro-
teasome and ubiquitination (Figure 1B). Both have been previ-
ously implicated in VACV genome replication (Satheshkumar
et al., 2009; Teale et al., 2009). SiRNA-mediated depletion of
proteasome subunits caused a nearly complete block in late viral
gene expression (Figure 2A). For confirmation, we determined
the virus yield in the presence of MG132, a proteasome inhibitor,
and UBEI-41, an inhibitor of the cellular E1 ubiquitin-conjugating
enzyme UBA1. Both decreased viral yield by 3 logs, similar to
cycloheximide (CHX), a protein synthesis inhibitor (Figure 2B).
When infection with VACV strains that express EGFP specifically
from an early (E-EGFP-VACV) or a late (L-EGFP-VACV) promoter
was analyzed by flow cytometry, we found that the inhibitors
blocked late but not early viral gene expression (Figure 2C).
This suggested that early steps in the virus lifecycle, such as
virus binding and endocytosis, were not impacted by these
inhibitors. To confirm this, we tested whether the effects of
MG132 and UBEI-41 could be circumvented by forcing fusion
of virions at the plasma membrane with low pH. This treatment
results in deposition of viral cores into the cytoplasm, effectively
bypassing the need for endocytosis (Mercer and Helenius,
2008). Consistent with a postpenetration block, the inhibitors
could not be bypassed upon low pH treatment (Figure 2D). Viral
yield, late gene expression, and inhibition after bypass were also
affected when using the more specific proteasome inhibitor,
Velcade (Figure S3). Thus, as reported by Teale et al. and
Satheshkumar et al. (Satheshkumar et al., 2009; Teale et al.,
2009), we found that proteasomes and UBA1 had no role in virus
endocytosis and penetration.
Next, we addressed genome uncoating. The efficient release
of viral DNA from internalized cores is of interest because
poxvirus particles and cores are extremely stable when exposed
to desiccation, denaturants, proteases, extremes of tempera-
ture, etc. (Essbauer et al., 2007; MacCallum and McDonald,
1957; Malkin et al., 2003).
Using a microscopy-based core stabilization assay that relied
on immunofluorescence staining of released cores, Satheshku-
mar and coworkers reported that inhibition of proteasome
activity had only a minor impact on genome uncoating (Sathesh-
kumar et al., 2009). Although over a 2-fold increase in core stabi-
lization was observed in the presence of MG132, they concluded
that inhibition of proteasome activity may delay or reduce
uncoating, but the effect was not sufficient to account for the
reduction in infectivity.
In light of these previous findings and the observation that
VACV cores are rapidly and efficiently disassembled during
entry into a new host cell (Joklik, 1964b; Magee and Miller,
1968), we found it conceivable that proteasome-directed coreFigure 1. VACV RNAi Screen and Functional Map of Host Factors Req
(A) Outline of screening and bioinformatic procedures.
(B) Host factors in larger functional clusters that interact or share functional anno
functional annotation cluster in which they were present (Figure S2). Functional clu
white boxes with dashed outlines. Yellow lines between genes of different cluste
genes within the same functional cluster include lower confidence (>0.35) STRIN
are indicated as inverted arrowheads. Functional gene clusters are pictured in th
Celldegradation was directly connected to DNA release. To further
investigate this possibility, we followed the fate of individual
viruses and cores by fluorescence microscopy using a virus in
which the core protein A5 was tagged with EGFP (Mercer and
Helenius, 2008) and by immunofluorescence staining of the
viral membrane protein L1 (Schmidt et al., 2011). HeLa cells
were incubated at a multiplicity of infection (MOI) of 10 for 4 hr,
a time sufficient for virions to enter and undergo genome
uncoating. Intact virions that still contained the viral membrane
were yellow (closed arrowheads), and internalized, released
viral cores devoid of membrane were green (open arrowheads).
When the cores in control cells were quantified (Figure S4),
few were observed (25–50/cell; green) (Figure 2E; untreated
[UNTR]). However, in the presence of CHX, which prevents
core breakdown and genome uncoating (Joklik, 1964b), intact
cytoplasmic cores numbered 275–320 per cell (Figure 2E;
CHX). The same was observed when the proteasome was
inhibited with MG132 (250–300/cell) (Figure 2E; MG132). UBEI-
41 had virtually no impact on core breakdown (50–60 cores/
cell) (Figure 2E; UBEI-41). This suggested that protein synthesis
and the proteasome were needed for uncoating, but UBA1
was not.
When the state of cytoplasmic cores after entry in the pres-
ence of MG132 was investigated using electron microscopy,
we could confirm that viral cores remained intact (Figure 2F,
MG132; Figure S5). While core expansion occurred (Figure S6),
it was evident that the genome (i.e., the electron dense material
within the cores) was not released (Figure 2F; blow-up). Electron
microscopy also showed that, while UBEI-41 did not inhibit core
breakdown, it prevented formation of viral DNA replication
factories (Figure 2F; UBEI-41). This was consistent with previous
reports that ubiquitination is needed for DNA replication (Sa-
theshkumar et al., 2009; Teale et al., 2009). Taken together, the
results suggested, somewhat paradoxically, that proteasomes
were needed for breakdown of the core, whereas ubiquitination,
which normally serves to prepare substrates for degradation,
was required for a subsequent step, one preceding DNA
replication.
The microscopy-based uncoating assays used by Satheshku-
mar and coworkers and here by us rely on core destabilization as
an indicator of genome uncoating. However, the release of
parental genomes from incoming viral cores is not analyzed.
Thus, it was possible that the viral DNA was released from viral
cores in the presence of MG132, but the cores themselves
were not degraded in the absence of proteasome activity. To
directly monitor release of incoming viral DNA as a consequence
of core breakdown, we used immunofluorescence staining for
the viral protein I3L that is bound to the viral DNA (Welsch
et al., 2003). That antibodies directed against this protein can
be used to detect uncoated parental VACV DNA in the absenceuired for Infection
tations are depicted. Individual genes were assigned to the highest enriched
sters identified by DAVID with simplified annotations (Table S2) are pictured as
rs indicate high-confidence (>0.9) STRING interactions, while those between
G interactions. Selected genes not found within a functional annotation cluster
eir approximate cellular location.
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Figure 2. Proteasome but not E1-Activating Enzyme Function Is Required for VACV Genome Uncoating
(A) RNAi-mediated silencing of proteasome subunits PSMA1 and PSMB3 impair VACV infection. Representative images from the screen are displayed with nuclei
in red and infected cells in green.
(B) Proteasome (MG132) and E1-activating enzyme (UBEI-41) inhibitors block VACV production (MOI 1; 24 hpi; 10 mM AraC, 10 mg/ml CHX, 25 mMMG132, and
50 mM UBEI-41 used throughout).
(C) MG132 and UBEI-41 allow for early but not late VACV gene expression. Cells were infected with VACV (MOI 1), expressing EGFP from either an early (Early) or
a late (Late) promoter. Infectionswere performed in the presence of the indicated inhibitors. Cells were harvested 6 hpi and analyzed for the number of early or late
EGFP-expressing cells, respectively. Cells infected in the presence of CHX or AraC were used as controls.
(D) MG132 and UBEI-41 inhibit VACV infection after internalization. VACV-EGFP MVs (MOI 1) were bound to cells for 1 hr in the presence of inhibitors. Cells were
then washed, treated with pH 7.4 or pH 5.0 media for 5 min, washed, and media containing the inhibitors added back. Cells were analyzed by flow cytometry for
EGFP at 6 hpi.
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Figure 3. Polyubiquitination of VACV Cores
Facilitates Their Degradation and Subse-
quent Genome Uncoating
(A) MG132 prevents VACV genome release, and
UBEI-41 blocks viral DNA replication. Cells were
infected (MOI 10) in the absence of inhibitors
(UNTR) or in the presence of MG132 or UBEI-41.
Cells were fixed at 4 hpi and immunofluorescence
against the viral DNA binding protein, I3, per-
formed, followed by staining of nuclei with Draq5.
In all images, nuclei are colored red and I3 staining
is in green. Cells treated with CHX, which prevents
genome release, or AraC, which allows for release
of parental genomes, but not their replication,
served as controls for the assay. Scale bars,
10 mm. The number of cells positive for parental
DNA staining (I3 spot formation) under each
condition is displayed as the mean ± SD (right).
(B) VACV core proteins are packaged in a poly-
ubiquitinated state. Immunoblots directed against
total (mono and poly) ubiquitin were performed on
1.0, 2.5, and 5.0 mg of purified VACV MVs (left), on
2.5 mg of whole (W) VACV MVs, or MVs separated
into core (C) andmembrane (M) fractions (right). As
a control for the detection of ubiquitin, 100 mg of
cell lysate (Cells) was used. Experiments were
performed in triplicate and representative blots
shown.
(C) Viral core proteins are positive for K48-, but
not K63-linked ubiquitin chains. Immunoblots
directed against K48- or K63-specific ubiquitin
chains were performed on whole (W), core (C), and
membrane (M) fractions of VACV MVs. One
hundred micrograms of cell lysate was used as
a control for each antibody (Cells).
(D) Late addition of MG132 or UBEI-41 does not
impede late viral gene expression. Cells were
infected (MOI 1) with VACV-EGFP-LATE. Either
10 mM AraC or 50 mM UBEI-41 were added at the
indicated times. Infection was allowed to proceed
for a total of 12 hr before cells were harvested and
analyzed by flow cytometry for EGFP expression.
Values are displayed as the percentage of cells
expressing late genes relative to untreated in-
fected control cells at 12 hpi.
(E) Inhibition of E1-ligase function at 6 hpi impedes
production of infectious virus. Cells were infected
with VACV MVs (MOI 1) and AraC or UBEI-41
added at either the time of infection (0) or after
6 hr (6). Cells were harvested 24 hpi, and the
progeny virus was purified by banding (Figure S8), followed by titration for plaque-forming units/ml. (A)–(C) Experiments were performed in triplicate and
representative images shown. (D) and (E) Experiments were performed in triplicate and displayed as the mean ± SD.
See also Figures S7 and S8.of viral replication has been demonstrated (Domi and Beaud,
2000; Welsch et al., 2003). While unable to access the antigen
in intact cores (Figure S7), antibodies to I3L stained cytoplasmic(E) VACV core degradation is proteasome-, but not E1-activating enzyme-depen
MG132, or UBEI-41. At 4 hpi, cells were fixed and intact virions identified by immu
intact virions aremarked by closed arrowheads and free green cytoplasmic cores
number of cores per cell under each condition displayed as mean ± SEM (right)
(F) Electron microscopy (EM) shows that MG132 and UBEI-41 inhibit distinct stag
EM. Intact viral cores are indicated by arrowheads. Blowup of virion (MG132) ind
500 nm. All experiments have been performed in triplicate and displayed as the
See also Figures S3, S4, S5, and S6.
Cellviral DNA after release from incoming cores (Figure 3A). Later in
infection, it also stained the I3L complexed with viral DNA in
the large perinuclear virus factories. When control cells weredent. Cells were infected with WR-EGFP-A5 (MOI 10) in the presence of CHX,
nofluorescence against the viral membrane protein L1R. Representative yellow
by open arrowheads. Experimentswere performed in triplicate, and the average
(Figure S4). Scale bars, 10 mm.
es of the VACV lifecycle. Cells treated as in (F) (MOI 10; 4 hpi) were analyzed by
icates that the electron dense viral genome is still within the core. Scale bars,
mean ± SD (B)–(D) or representative images displayed (A), (E), and (F).
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Figure 4. A Cullin3 E3-Ligase Complex Is Required for VACV DNA Replication
(A) MG132 and UBEI-41 block VACV DNA replication site formation. Cells were infected with VACV MVs (MOI 1) in the presence of AraC, MG132, or UBEI-41.
Cells were fixed and stained for DNA at 4 hpi. Representative images (left) scale bars, 2 mm; mean ± SD of triplicate experiments (right).
(B) MG132 and UBEI-41 block VACV DNA replication after uncoating. Cells were infected with VACV MVs (MOI 1) in the presence of AraC. At 6 hpi, cells were
washed and released from AraC (No Inh.) or shifted into MG132 or UBEI-41. Cells were fixed at 12 hpi and assessed for the presence of cytoplasmic DNA
replication sites.
(C) RNAi against Cul3 or Rbx1, but not Cul1, impairs VACV infection. Representative images from the screen are displayed with nuclei in red and infected cells in
green.
(D) Silencing of Cul3 or Rbx1, but not Cul1, reduces virus production. Cells were reverse transfected with 20 nM (final concentration) of three independent siRNAs
directed against either Cul3, Rbx1, or Cul1. After 72 hr, cells were infected with VACV MVs (MOI 1). Twenty-four hours later, cells were harvested and lysates
titered for plaque-forming units/ml (left). Immunoblot analysis of Cul3, Rbx1, and Cul1 after siRNA mediated silencing for 72 hr. Immunoblot analysis directed
against actin was used as a loading control (right; representative blots shown).
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infected for 4 hr at a MOI of 10 and the viral DNA visualized by
anti-I3L, replication factories and cytoplasmic I3 staining were
seen (green) (Figure 3A; UNTR). With CHX present to prevent
early gene expression and genome release, only 5% of cells
had I3L-positive spots in the cytoplasm. In the presence of
cytosine arabinoside (AraC), an inhibitor of viral DNA replication,
78% of cells contained cytoplasmic I3L spots, indicating that
incoming viral DNA had been released, but not replicated. Cells
infected in the presence of MG132 were positive for diffuse cyto-
plasmic I3L staining, but did not contain I3L-positive viral DNA
spots. This showed that, even though expression of I3L (an early
protein) had occurred, viral genomes had not been released
(Figure 3A; MG132). In contrast, UBEI-41-treated cells displayed
diffuse cytoplasmic I3L staining and I3L-positive spots, as seen
in AraC-treated cells, confirming that viral genomes were
released but not replicated. Collectively, these results showed
that the proteasome and UBA1 acted in distinct steps in the early
infection cycle: proteasomes in core breakdown and DNA
release and UBA1 (and thus ubiquitination) in replication of
released viral DNA.
VACV Core Proteins Are Packaged in a K48-
Ubiquitinated State to Mediate Proteasome-Dependent
Genome Uncoating
That core degradation was not dependent on UBA1 suggested
that ubiquitin must have been added to core proteins prior to
virus entry. Proteomic analysis of isolated VACV virions has indi-
cated that ubiquitin accounts for 1–3 mole percent of total
protein (Chung et al., 2006). However, the location of this ubiqui-
tin within the viral particle and the potential role of this host
protein in the virus lifecycle have not been investigated.
Immunoblot analysis on highly purified VACV virions
confirmed that they contained a striking amount of ubiquitin (Fig-
ure 3B, left). The molecular weight of the detected bands indi-
cated that these were ubiquitin-conjugated proteins and not
free ubiquitin. To assess the location of the ubiquitin-conjugated
proteins, virions were separated into membrane and core frac-
tions (Mercer and Traktman, 2003). Immunoblot analysis on
these fractions indicated that the vast majority of the ubiquiti-
nated factors were components of the viral core (Figure 3B,
right). Using lysine-48- and lysine-63-linked polyubiquitin
specific antibodies, we showed that only lysine-48-linked ubiqui-
tinated proteins were present (Figure 3C). Since lysine-48-linked
ubiquitin chains mark proteins for proteasomal degradation
(Clague and Urbe´, 2010; Komander, 2009), it was evident that
this was the mechanism that triggered proteasome-mediated
genome uncoating.(E) Silencing of Cul3 and Rbx1, but not Cul1, reduces late but not early viral gene e
by infection with VACV (MOI 1), expressing EGFP specifically from an early or a l
expressing early and late EGFP, respectively. Cells infected in the presence of C
(F) Cul3 and Rbx1 are required for VACV DNA replication site formation. Cells in w
with VACVMVs (MOI 1). At 4 hpi, cells were fixed, stained with Draq5, and analyze
triplicate and displayed as mean ± SD (A, B, and D–F).
(G) Model of VACV core ubiquitination, core degradation/genome uncoating, an
ubiquitinated in a K48-linked fashion. Upon infection of naive cells, fusion of viral a
A first round of cellular proteasome action directs the degradation of the ubiquitin
second round of proteasome action serves to initiate replication of the releas
accessible (green); proteasomes (gray bullets); cullin-based ubiquitin ligase com
CellSince ubiquitination of core proteins must occur during virion
production in infected cells, we asked whether infectious virus
could be produced if ubiquitination was inhibited late in infection.
Addition of AraC at 6 hr had little effect on late viral gene expres-
sion (Figure 3D, white) and only marginally reduced the 24 hr
virus yield (Figure 3E, white). As late genes are expressed from
newly replicated genomes, this indicated that, by 6 hpi, viral
DNA replication and late gene expression was sufficient for
significant virus production. When UBEI-41 was added at
6 hpi, again there was no impact on late viral gene expression
(Figure 3D, gray). However, unlike AraC, which had little effect
on virus yield, addition of UBEI-41 after 6 hr prevented the
production of infectious virus (Figure 3E, gray). We were, in
fact, unable to isolate virus particles from infected cells treated
with UBEI-41 from 6 hpi (Figure S8). This indicated that there
are at least two steps in the VACV infectious cycle that require
ubiquitination: not only viral DNA replication after genome
uncoating, but also assembly of progeny virus.
A Cullin-3 Ubiquitin Ligase Complex Is Required
for VACV Genome Replication
It has been reported that poxvirus DNA replication is inhibited in
MG132- and Velcade-treated cells (Satheshkumar et al., 2009;
Teale et al., 2009). Could this observation be explained by the
upstream inhibition of uncoating, or was there a second step in
the early infection program that required ubiquitination and the
proteasome? After confirming that both MG132 and UBEI-41
prevented VACV replication site formation (Figure 4A), we used
an AraC wash-out assay to test for direct effects on replication.
AraC has no impact on the uncoating of viral genomes, but
prevents their replication. Cells were infected in the presence
of AraC for 6 hr to allow uncoating, but to stop replication of
incoming genomes. AraC was then washed out or replaced
with either UBEI-41 or MG132. Infection was allowed to proceed
for an additional 6 hr, after which cells were analyzed for viral
replication sites (Figure 4B). In control cells without a second
inhibitor (No Inh.), replication site formation was normal.
However, in the presence of UBEI-41 or MG132, the formation
of viral replication sites did not occur. These results confirmed
that the initiation of DNA replication requires both a ubiquitination
step and proteasome-mediated degradation.
Reasoning that a cellular ubiquitin ligase was likely to be
involved, we turned to the hits in the RNAi screen. The ubiquitin
functional annotation cluster (Figure 1B) contained two compo-
nents of the BCR E3 ubiquitin-ligase complex: Cullin3 (Cul3)
and RING-box protein 1 (Rbx1). Images from the screen indi-
cated that depletion of these factors resulted in the absence ofxpression. Cells were subjected to siRNA-mediated silencing as in (D) followed
ate promoter. Cells were harvested 6 hpi and analyzed for the number of cells
HX or AraC were used as controls.
hich Cul3, Rbx1, or Cul1 had been silenced (20 nM siRNA; 72 hr) were infected
d for the presence of viral DNA replication sites. Experiments were performed in
d genome replication. During assembly of VACV MVs, viral core proteins are
nd cellular membranes releases the ubiquitinated viral core into the cytoplasm.
ated core and concomitant genome release. A Cul3-based ubiquitin ligase and
ed viral genomes. Ubiquitination events: new (red); nonaccessible (yellow);
plex (gray crescents).
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late gene expression (Figure 4C). A requirement for Cul3 and
Rbx1 was validated with three independent siRNAs each. Deple-
tion of either factor decreased the 24 hr viral yield by two logs
(Figure 4D; left). Silencing of Cullin-1 (Cul1), a component of
the SCF E3 ubiquitin-ligase complex that was not a hit in the
screen, had no impact (Figure 4C and 4D; left). The knockdown
efficiency of these siRNAs was confirmed by Western blot (Fig-
ure 4D; right).
Additional experiments were performed using the siRNA with
the strongest knockdown efficiency (Cul3-1, Rbx1-3, and Cul1-
2). Depletion of Cul3 or Rbx1 was found to significantly decrease
late but not early gene expression (Figure 4E), mirroring the effect
of AraC and confirming a defect in DNA replication. In line with
this, Cul3 and Rbx1 knockdown inhibited the formation of cyto-
plasmic DNA replication factories (Figure 4F). We concluded that
UBA1, a Cul3 ubiquitin ligase, and the proteasomewere required
to initiate the replication of uncoated VACV DNA.
DISCUSSION
Our results demonstrated that large-scale RNAi screening
can, despite inherent problems and pitfalls (off-target effects,
insufficient knockdown, cell population context effects, incom-
plete genome annotation, etc. [Cherry, 2009; Mohr et al.,
2010]) serve as a valuable tool in the study of pathogen/host
interactions. The positive outcome relied in this case on a robust
image-based assay, on supervised classification of cellular
phenotypes, a separation of indirect and direct effects of
siRNAs, and on improved bioinformatics analysis to identify
gene clusters (Snijder et al., 2012). That the screening data, anal-
ysis, and bioinformatic tools used for the purpose of this study
are publically available will be of general usefulness in the anal-
ysis of future screening data.
Among the 188 hits, we identified numerous clusters in which
multiple hits occurred in the same pathway or complex.
Regarding the validity of the final hit list, we are encouraged by
how many of the hits corresponded to factors identified earlier
as essential genes in VACV infection. Validation studies with
two of the clusters as a starting point allowed us to extend
previous findings regarding a role for ubiquitination in DNA repli-
cation (Satheshkumar et al., 2009; Teale et al., 2009) and
discover a new role for ubiquitination and the proteasome in virus
assembly and uncoating (Figure 4G). We could thus confirm the
value of the hit list as a resource for functional studies of poxvirus
host cell interactions.
Our results showed that ubiquitination comes into play as an
essential process already during the assembly of VACV particles
in virus factories located in the cytoplasm of producer cells. Core
proteins undergo extensive K48-linked polyubiquitination. This is
consistent with the accumulation of ubiquitin observed in
poxvirus replication sites and the detection of ubiquitin within
purified VACV particles (Chung et al., 2006; Nerenberg et al.,
2005). Polyubiquitination is probably an essential step in virus
assembly, because inhibition of the E1 ubiquitin-activating
enzyme prevented the generation of viral particles. VACV
encodes one ubiquitin ligase, p28, which localizes to VACV repli-
cation sites (Nerenberg et al., 2005). However, as this protein is
not required for virus production in tissue culture, it is unlikely to1044 Cell Reports 2, 1036–1047, October 25, 2012 ª2012 The Authobe the ligase responsible for the ubiquitination of viral core
proteins. Future work is needed to identify the core components
that are ubiquitinated as well as the ubiquitin ligase(s) respon-
sible. During egress from the viral factory, the viral membrane
may protect the ubiquitinated core proteins from the degradation
machinery.
After macropinocytic internalization of VACV into a new host
cell and low pH-dependent membrane fusion, polyubiquitinated
cores are released into the cytosol. They immediately undergo
activation marked by major expansion in size, a step that does
not require early gene expression (Dales, 1963; Ichihashi et al.,
1984; Pedersen et al., 2000). The expanded cores serve as the
site for early gene transcription (Joklik, 1964a; Magee andMiller,
1968). That they are not yet substrates for proteasome-mediated
uncoating suggests that the ubiquitin chains are not accessible.
For degradation of the core and uncoating of the DNA, early
genes have to be expressed. One or more of the early proteins
are likely responsible for making the ubiquitinated core proteins
accessible as substrates for the proteasome. The core particle is
destroyed and some of the core components, such as the A5
protein, degraded.
As a result of the proteolysis, the viral DNA genome is released
and the core itself is no longer recognizable as a structure in
the cytosol. That UBA1 activity is not required indicates that
the ubiquitin present in the core is sufficient to mediate genome
uncoating. Although proteasome function has been implicated in
the regulation of viral trafficking, replication, egress, and immune
evasion (reviewed in Banks et al., 2003), a direct role for protea-
somes in the uncoating of viruses or viral capsids has not, to our
knowledge, been observed before.
It was previously reported that viral DNA replication requires
ubiquitination and proteasome activity (Satheshkumar et al.,
2009; Teale et al., 2009). Our results extended these findings
to show that replication of the viral DNA depends on Cul3 and
Rbx1, two components of an important, multifunctional E3-
ligase family (Petroski and Deshaies, 2005). As recently reviewed
(Barry et al., 2010), VACV encodes at least four Cul3 substrate
adapters: A55R, C2L, C5L, and F3L (Beard et al., 2006; Froggatt
et al., 2007; Pires de Miranda et al., 2003). Although each of
these is required for VACV virulence, they are not essential for
replication in tissue culture. This implies that they are not the
adaptor proteins used by Cul3 to facilitate VACV DNA replica-
tion. While the substrates are yet to be identified, one possibility
is that they represent remaining DNA-associated proteins to be
removed before replication.
The proteasome thus plays a central role in at least two steps
in the replication cycle of VACV. Collectively, the RNAi screen
and follow-up studies, like those described here, are likely to
provide a starting point for detailed cell and molecular biology
analysis of poxvirus-host cell interactions, and theymay facilitate
the development of novel antipoxvirus agents that target the host
cell rather than viral factors.EXPERIMENTAL PROCEDURES
RNAi Screen
HeLa MZ cells from Marino Zerial (MPI-CBG, Dresden) were maintained at
37C and 5% CO2 in Dulbecco’s modified Eagle’s medium (DMEM; GIBCOrs
BRL) supplemented with 10% fetal calf serum (FCS) and glutamax. All liquid-
handling steps, including preparing cell plates, virus infection, and cell fixation,
were performed on a Freedom Evo200 liquid-handling robot (Tecan) set up
specifically for this purpose. Seeding, fixing, and DAPI staining of the cells
was performed using a Matrix Wellmate Microplate Dispenser (Thermo
Scientific).
RNA interference against the 6,979 gene targets was achieved with
three independent siRNAs targeting each (siRNAs #1 and #2 from QIAGEN
druggable genome version 2 and siRNA #3 from QIAGEN druggable
genome version 3) or three independent siRNAs from Ambion for sec-
ondary screening (custom ordered). Each siRNA was tested in triplicate.
Experiments were conducted in a 384 well plate format, amounting to 210
plates for the primary screen (see Extended Experimental Procedures for plate
layout).
All images were acquired on automated wide field cellWoRx microscopes
(Applied Precision) with a 10X objective, and 23 2 binning per pixel. Multiwell
plates were loaded onto the cellWoRx microscopes using Freedom Evo
robotics from Tecan. Three by three directly adjacent images were taken per
well, covering over 90% of each well surface. An image-based autofocus
was performed on the DAPI signal for each imaged site. The images were
recorded with 12-bit charge-coupled device (CCD) cameras and stored as
individual 16-bit uncompressed tagged image file format (TIFF) files per
imaged site and per channel.
Computational Image Analysis, Supervised Classification of Cellular
Phenotypes, Hit Scoring, DAVID Annotation Clustering Network, and
Combined DAVID/STRING Functional Gene View
Please refer to the Extended Experimental Procedures for details on bio-
informatics methodology.
Cells, Viruses, and Reagents
HeLa ATCC and HeLa MZ cells were maintained at 37C and 5% CO2 in
DMEM (GIBCO BRL) supplemented with 10% FCS and glutamax. Wild-type
vaccinia virus (strain WR), (EGFP-VACV) containing the EGFP gene driven by
a synthetic VACV early-late promoter inserted into the thymidine kinase (tk)
locus, and vaccinia virus containing EGFP-tagged versions of the core protein
A5 (WR-EGFP-CORE) were generated as previously described (Mercer and
Helenius, 2008). AraC, CHX, and MG132 were purchased from Sigma.
UBEI-41 (PYR-41) was purchased from Calbiochem.
Flow Cytometry Analysis and Perturbant Analysis
To analyze temporal viral gene expression, cells were infected with recombi-
nant VACV viruses that express EGFP from the J2R early viral promoter
(E-EGFP-VACV) or the F18R late viral promoter (L-EGFP-VACV). Cells were
infected at an MOI of 1. For all experiments, cells were harvested at 6 hpi
and prepared as previously described (Mercer and Helenius, 2008). Cells ex-
pressing early or late EGFP were gated based on uninfected controls. CHX
and AraC served as specific controls for inhibition of early and late gene
expression, respectively. Flow cytometry was performed on a BD Bioscience
Calibur System. For each sample, 10,000 cells were analyzed. For all experi-
ments, cells were infected with E- or L-EGFP-VACV in the presence of drug
at an MOI of 1, unless otherwise indicated.
Viral DNA Uncoating
HeLa cells were infected in the presence of CHX (25 mg/ml), AraC (10 mM),
MG132 (25 mM), or UBEI-41 (50 mM). Cells were then infected at an MOI of
10. Four hpi cells were fixed and stainedwith antisera directed against vaccinia
I3L protein (1:500) (a generous gift of Jacomine Krijnse-Locker; University of
Heidelberg, Germany) followed by Alexa594 secondary antibody (1:1000)
and draq5 (1:5000). Imageswere acquired on a Zeiss LSM510 confocalmicro-
scope at 100X oil immersion objective.
Virion Ubiquitin Immunoblot Analysis
One to five micrograms of band-purified wild-type (WT) MVs were left
untreated or were fractionated into membrane and core components as previ-
ously described (Mercer and Traktman, 2003). Samples were separated on
SDS-PAGE, transferred to nitrocellulose, and immunoblot analysis was per-Cellformed for total mono- and polyubiquitination (clone FK2, Enzo Life sciences),
k48-linked ubiquitin chains (clone Apu2; Millipore), or K63-linked ubiquitin
chains (clone Apu3; Millipore).
siRNA Transfection
For siRNA transfection, 25,000 HeLa ATCC cells were seeded in a 24 well dish
1 day prior to transfection. A 20 nM final concentration of siRNA was used to
transfect cells 72 hr prior to infection. siRNAs were purchased from QIAGEN:
Cullin1: (1) Hs_CUL1_6; (2) Hs_CUL1_5; (3) Hs_CUL1_3, Cullin3: (1)
Hs_CUL3_5; (2) Hs_CUL3_8; (3) Hs_CUL3_10, and Rbx1: (1) Hs_RBX1_6; (2)
Hs_RBX1_5; (3) Hs_RBX1_10.
siRNA Depletion Confirmation
Immunoblot analyses to confirm the depletion of target proteins by siRNAwere
performed on siRNA-treated cells. Antibodies were directed against Cullin1
(1:250; Zymed Laboratories), Skp1 (1:1000; Cell Signaling Technology), or
Rbx1 (1:250; Sigma-Aldrich). Cul3 antibody (1:1000) was a generous gift of
Prof. M. Peter (Institute of Biochemistry, ETH Zurich).
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figures, two tables, and a supplemental network visualization algorithm and
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